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Abstract The evidence from trials of statin therapy sug-
gests that benefits in cardiovascular disease (CVD) event
reduction are proportional to the magnitude of low-density
lipoprotein cholesterol (LDL-C) lowering. The lack of a
threshold at which LDL-C lowering is not beneficial, in
terms of CVD prevention observed in these trials, is sup-
ported by epidemiological and genetic studies reporting the
cardio-protective effects of lifelong low exposure to
atherogenic cholesterol in a graded fashion. Providing that
intensive LDL-C lowering is safe, these observations sug-
gest that many individuals even at current LDL-C treat-
ment targets could benefit. Here, we review recent safety
and efficacy data from trials of adjunctive therapy, with
LDL-C lowering beyond that achieved by statin therapy,
and their potential implications for current guideline tar-
gets. Finally, the application of current guidance in the
context of pre-treatment LDL-C concentration and
deployment of statin therapy is also discussed. The number
of patients requiring treatment to prevent a CVD event with
statin treatment has been shown to differ markedly
according to the pre-treatment LDL-C concentration even
when absolute CVD risk is similar. It produces more
likelihood of benefit when absolute LDL-C reduction is
greater which is largely dependent on pre-treatment LDL-C
concentration. This also has to be taken in consideration
when deploying new agents like proprotein convertase
subtilisin/kexin type 9 monoclonal antibodies. Patients
with highest LDL-C concentration despite maximum statin
and ezetimibe therapy will attain most absolute LDL-C
reduction when treated with proprotein convertase
subtilisin/kexin type 9 monoclonal antibodies, hence ben-
efit most in term of CVD risk reduction.
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Introduction
Molecular and cellular studies have established a central
role for low-density lipoprotein cholesterol (LDL-C) in the
pathogenesis of atherosclerotic plaques, and their clinical
sequelae including coronary heart disease (CHD) and
ischaemic stroke. Epidemiological data confirm an inde-
pendent positive association between LDL-C and cardio-
vascular disease (CVD) risk and suggest that this
relationship extends to low LDL-C levels [1, 2]. The sig-
nificance of lifetime exposure to elevated LDL-C is
underscored by genetic studies in individuals with
heterozygous familial hypercholesterolaemia (HeFH) who
appear to be at considerable excess risk of premature
atherogenesis and CVD [3]. Conversely, in populations
with genetically determined low LDL-C, CVD risk
approximately halves for every 1 mmol/L (39 mg/dL)
reduction in LDL-C [4].
Efforts to reduce LDL-C with statin therapy in at-risk
individuals have been largely successful in reducing CVD
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risk, driven largely by a reduction in events rates of
myocardial infarction (MI) with no apparent threshold at
which LDL-C lowering is not associated with reduced risk
[5, 6]. Recent trial data for therapies targeting secreted
circulating protease proprotein convertase subtilisin/kexin
type 9 (PCSK9) or the Niemann–Pick C1-like 1 (NPC1L1)
protein suggest that incremental lowering above and
beyond that achieved with statin treatment is possible
[7–9]. Furthermore, the use of adjunctive therapy can
reduce LDL-C levels below targets recommended by
guidelines [10–12]. We evaluate the evidence for residual
risk at current LDL-C treatment goals and the implications
of recent trial findings for existing guidelines. The safety of
LDL-C reductions to very low levels is discussed with
reference to genetic, epidemiological and clinical studies.
Efficacy of LDL-C lowering for CVD event
reduction
Genetic and population data
Identification of LDL-lowering alleles of PCSK9 has
allowed the direct effect of very low LDL-C on CVD risk
to be determined by Mendelian randomisation, independent
of confounding variables such as diet, medical therapy and
weight [1, 13]. In 2006, genotyping of 13,342 individuals
enrolled in the Atherosclerosis Risk in Communities
(ARIC) study provided evidence of protection against CVD
in a graded fashion with LDL-C levels, despite a high
prevalence of other risk factors [14]. Mutations that low-
ered LDL-C by around 1 mmol/L (40 mg/dL) reduced
incident CHD by around 88%, whereas lowering by around
0.5 mmol/L (20 mg/dL) reduced events by 50%. These
effects are bigger than seen in randomised controlled trials
(RCTs) of for example statins, emphasising the importance
of a lifelong lower LDL-C, over shorter-term reduction
later in life.
Mendelian randomisation studies have also demon-
strated the importance of lifetime exposure to LDL-C, with
genetically determined low LDL-C associated with greater
magnitudes of CHD risk reduction as compared with LDL-
C lowering to equivalent values in the CTT meta-analyses
of statin trials [4]. Table 1 summarises some of the most
common conditions with genetically determined low LDL-
C.
Interventional studies
Taken together, the statin trial data suggest that the abso-
lute benefits of treatment are related to an individual’s risk
of atherosclerotic CVD and the absolute reduction in LDL-
C that is achieved [15]. Meta-analyses undertaken by the
Cholesterol Treatment Trialists’ (CTT) Collaboration on
statin trials suggest that a 1.0 mmol/L reduction in LDL-C
is associated with a relative risk (RR) of 0.90 (95% CI
0.87–0.93) for all-cause mortality, or in other words, a
reduction of 10%. Major coronary events were similarly
reduced by 24% (RR 0.76, 95% CI 0.73–0.79) and stroke
by 15% (RR 0.85, 95% CI 0.8–0.89) (Fig. 1) [5, 6]. The
combined CVD endpoint of CHD plus stroke decreased by
22% (RR 0.78, 95% CI 0.76–0.80) per 1.0 mmol/L
reduction in LDL-C [5]. Importantly these benefits were
observed irrespective of baseline cholesterol concentration
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(even with LDL-C\2 mmol/L) and there was no evidence
to suggest that achieving low LDL-C levels resulted in any
adverse effects. These findings imply that patients at high
risk of atherosclerotic occlusive disease should benefit
further from achieving the lowest concentrations of LDL-C
possible, below even the targets from the US National
Cholesterol Education Programme and European Society
of Cardiology (ESC) of\2.6 mmol/L [10, 11]. For indi-
viduals at very high risk, the European guidelines recom-
mend to achieve both a lower target of \1.8 mmol/L
(\70 mg/dL) and an LDL-C reduction from baseline of at
least 50%, where baseline LDL-C is between 1.8 and
3.5 mmol/L (70 and 135 mg/dL) [11]. Importantly, these
guidelines fundamentally differ from those provided by the
Fig. 1 Proportional effects on major vascular events per mmol/L LDL cholesterol reduction. MVE major vascular events, RR relative risk, CI
confidence interval. From Baigent et al. [6] with permission of the publisher (Elsevier, 2012)
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American Heart Association (AHA)/American College of
Cardiology (ACC) which do not provide a specific treat-
ment targets for LDL-C [16]. The recent ACC expert panel
consensus document features two particular developments
away from the AHA/ACC 2013 guidelines: the inclusion of
specific LDL-C targets and the suggestion to employ
adjunctive therapy (ezetimibe and PCSK9 inhibitors) to
achieve these targets where maximally tolerated statin
monotherapy is insufficient [17]. For patients with pre-
existing cardiovascular disease, without comorbidities on
statin therapy, the consensus suggests that if the C50%
reduction in LDL-C or if levels persist above 100 mg/dL,
additional LDL-C lowering approaches are warranted. In
the case of a patient with pre-existing CVD and LDL-C
C190 mg/dL, the corresponding LDL-C value at which
additional therapy may be considered is 70 mg/dL. This is
a significant step toward lowering the threshold for
adjunctive treatment and lowering the optimal LDL-C
target.
The Improved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT) study enrolled partici-
pants with a history of acute coronary syndrome to receive
simvastatin and ezetimibe or simvastatin alone [9]. The
addition of ezetimibe lowered LDL-C by around 24% and
resulted in a significantly lower risk of CV events after
7 years (hazard ratio 0.94, 95% CI 0.89–0.99, P = 0.016).
The magnitude of benefit seen with additional LDL-C
lowering was consistent with that reported in the CTT
meta-analyses [5, 6], a finding that lends support to the so-
called LDL hypothesis [18]. The absence of benefit in
reducing all-cause mortality or deaths from cardiovascular
causes in IMPROVE-IT was noteworthy, but not entirely
unexpected when considering that prior trials of intensive-
dose versus standard-dose statin therapy did not demon-
strate a mortality benefit and IMPROVE-IT was not pow-
ered to detect a difference in mortality [19].
Recent trials with the PCSK9 inhibitors evolocumab and
alirocumab suggest that profound reductions in LDL-C
may further reduce CV events despite a limited duration of
follow-up [7, 8]. In the two Open-Label Study of Long-
Term Evaluation against LDL-C (OSLER) studies [7],
participants who had completed one of the twelve phase 2
or 3 studies were assigned in a 2:1 ratio to receive either
one of two evolocumab doses (140 mg every 2 weeks or
420 mg monthly) in addition to standard therapy or stan-
dard therapy alone. LDL-C was reduced by 61% in the two
evolocumab treatment arms compared with standard ther-
apy, equating to a decrease in LDL-C from median base-
line levels of 3.95 mmol/L (120 mg/dL) in the parent
studies to 1.26 mmol/L (48 mg/dL) in evolocumab groups
at week 12 of the open-label studies. Patients in the evo-
locumab group had a corresponding reduction in CV events
as compared with those in the standard treatment group
(hazard ratio 0.47, 95% CI 0.28–0.78). Similarly, a post
hoc analysis performed on data from the Long-term Safety
and Tolerability of Alirocumab in High Cardiovascular
Risk Patients with Hypercholesterolemia Not Adequately
Controlled with Their Lipid Modifying Therapy (ODYS-
SEY LONG TERM) study also suggested a beneficial
effect of PCSK9 inhibition on major CV events compared
with placebo (hazard ratio 0.52, 95% CI 0.31–0.90).
ODYSSEY LONG TERM enrolled patients with HeFH
and those with at least CHD risk equivalent [8]. Inclusion
criteria specified patients on maximally tolerated statin
therapy with an LDL-C C1.8 mmol/L (70 mg/dL). At
baseline, mean LDL-C were 3.2 mmol/L (124 mg/dL).
Using alirocumab 150 mg every 2 weeks, mean reductions
in LDL-C of 1.2 mmol/L (46 mg/dL) were observed at
week 24.
Positive outcomes in OSLER, ODYSSEY and
IMPROVE-IT studies are also significant in light of the
failure of several other non-statin lipid lowering agents to
demonstrate clinical benefit [20, 21]. Further non-statin
pharmacological reduction in LDL-C using niacin has
recently been investigated in the Atherothrombosis Inter-
vention in Metabolic Syndrome With Low HDL/High
Triglycerides and Impact on Global Health Outcomes
(AIM-HIGH) study and Heart Protection Study 2–Treat-
ment of HDL to Reduce the Incidence of Vascular Events
(HPS2-THRIVE) [22, 23]. Despite previous studies
showing a reduction in non-fatal MI with niacin adminis-
tered as monotherapy to men with raised LDL-C [24], these
more recent studies examining the effects of niacin as add-
on therapy to statins in patients with pre-existing CVD
statin-lowered LDL-C have failed to demonstrate reduc-
tions in CVD or all-cause mortality. Given the lowering of
LDL-C and triglyceride with niacin, and benefits in raising
HDL-C, one may speculate that one of the off-target effects
of niacin may attenuate or reverse the clinical benefit that
improvement in lipid parameters offers. It is also possible
that the increase in HDLs cholesterol target was not asso-
ciated with an improvement in HDL functionality enough
to have an impact [25]. In conjunction with its known side
effects of hepatotoxicity, hyperuricemia and hyper-
glycemia, these outcomes trials have signalled the end of
niacin’s use.
Uncertainty exists around the use of another LDL-C
lowering strategy, cholesteryl ester transfer protein (CETP)
inhibition. Two outcome trials with different CETP inhi-
bitors have failed to show a benefit in terms of CVD risk
reduction [21, 26]. The Investigation of Lipid Level
Management to Understand its Impact in Atherosclerotic
Events (ILLUMINATE) trial enrolled patients with pre-
existing CVD or type 2 diabetes and those receiving
torcetrapib (CETP inhibitor) in addition to statin experi-
enced a 25% reduction in LDL-C and a 72% increase in
240 Clin Res Cardiol (2017) 106:237–248
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HDL-C [26]. Despite this, a significantly increased risk of
death in the torcetrapib group led to termination of the trial.
The cause for this excess mortality risk is not entirely clear;
however, as with niacin it is possible that off-target effects
such as raised blood pressure and increased levels of cir-
culating aldosterone, as well as increasing HDL-C without
a significant improvement in HDLs functionality may have
affected the primary outcome measure [27]. It is interesting
to note that post hoc analyses of the trial showed regression
of coronary atheroma with greater levels of HDL-C, which
was also seen to have an inverse relationship with CVD
events. The second outcomes trial using the CETP inhibitor
dalcetrapib reported less marked increases HDL-C in the
active treatment group (&30%) with minimal effects on
LDL-C and no benefit in reduction of CVD events [21]. Its
failure could be explained by the absence of any pre-trial
evidence suggesting a stabilising effect on atherosclerotic
plaques or the failure to meaningfully reduce LDL-C in the
trial [28]. More recent studies demonstrated that the effects
of dalcetrapib on atherosclerotic outcomes are determined
by polymorphism in adenylate cyclase type 9 gene [29, 30].
Safety of LDL-C lowering
It is well established that lifelong exposure to elevated
concentrations of LDL-C is associated with increased risk
of CV morbidity and mortality. There remain, however,
some scientific discussions regarding the safety of
aggressive LDL-C lowering and the effects of long-term
low levels on CV and overall health.
Clinical trials data
On-treatment LDL-C concentrations below a normal range
during extended follow-up in the setting of statin trials do
not appear to be associated with any adverse effects [31].
Among patients achieving LDL-C levels of\1.3 mmol/L
(50 mg/dL) on rosuvastatin in the JUPITER trial, there
were no reported differences in symptoms of myalgia,
muscle weakness or myopathy when compared to those
who did not meet target. A non-significant increase in
diabetes as an adverse event was observed among subjects
attaining a target of LDL-C \1.3 mmol/L (50 mg/dL);
depression and colon cancer were reported less frequently
in this group. In a meta-analysis performed by Sattar et al.
evaluating the risk of developing diabetes in patients on
statin therapy [32], a 9% increased risk of incident diabetes
was reported. Importantly, the small absolute risk for
developing diabetes was outweighed by the CVD benefit of
statins in the medium term, and change in LDL-C con-
centration was not associated with increased risk of inci-
dent diabetes. Preiss et al. carried out a further meta-
analysis of five studies randomising individuals, free of
diabetes at baseline, to standard- or intensive-dose statins
[33]. Based on a higher risk of developing type 2 diabetes
among participants receiving higher-dose statins, the dia-
betogenic effects of statins were suggested to be dose-
related.
The limited follow-up duration of phase 3 trials
involving PCSK9 inhibitors precludes a comprehensive
assessment of long-term safety; however, the profound
lipid lowering achieved offers the opportunity to analyse
the occurrence of adverse events with very low LDL-C
concentrations over the short term. In a comprehensive
analysis of data from the OSLER-1 and OSLER-2 studies
[7], the incidence of adverse events including elevation in
aminotransferase or creatinine kinase, muscular com-
plaints, and neurocognitive events did not appear to
increase among the 26% of patients enrolled achieving
LDL-C levels below 0.6 mmol/L (23 mg/dL). These data
should be interpreted with caution in light of the short
follow-up, more intensive visiting schedule with PCSK9
inhibition therapy versus standard of care and the open-
label nature of the OSLER study.
A similar finding was observed in the ODYSSEY
LONG TERM study [8]. Over a third of patients in the
alirocumab arm had two consecutive LDL-C measurements
\0.6 mmol/L (23 mg/dL) and adverse events were similar
when compared with the overall treatment group. While
not related in either study to the magnitude of LDL-C
reduction, neurocognitive defects were reported more often
in the group of patients receiving a PCSK9 inhibitor than
those on standard of care. Concerns regarding the impact of
PCSK9 inhibition on its role in the regulation of neuronal
apoptosis has led to demands from the FDA to evaluate
possible changes with treatment; however, to date there are
no data to support an association with the degree of LDL-C
lowering. A dedicated systematic review on the subject of
cognitive decline with LDL-C lowering on statin therapy
did not support any association [34]. Furthermore, neu-
rocognitive dysfunction has not been reported among
individuals with undetectable LDL-C resulting from
abetalipoproteinaemia [35], despite frequent problems with
absorption of fat soluble vitamins. Vitamin E transport in
particular is closely associated with LDL metabolism and
severe vitamin E deficiency is characteristic of abetal-
ipoproteinaemia [36]. Substantial LDL-lowering observed
in trials of PCSK9 inhibitors was shown to lower absolute
vitamin E levels, but not those normalised for cholesterol
[37]. While patients with abetalipoproteinaemia are unable
to form chylomicrons essential for absorption of vitamin E,
those treated with PCSK9 inhibition experience increased
catabolism of LDL, which is thought unlikely to impair
absorption or distribution of vitamin E. Despite the
requirement of free cholesterol for steroid hormone
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synthesis, no evidence of impairment in adrenal or gonadal
steroid hormone synthesis was found with PCSK9 inhibi-
tion, even in patients who experienced LDL reductions to
\0.4 mmol/L (\15 mg/dL) [37].
Genetic studies
Familial hypobetalipoproteinaemia (FHBL) is a hereditary
disorder of lipoprotein metabolism characterised by very
low levels of apolipoprotein B (apoB), and consequently
LDL-C. As such FHBL individuals are a good population
in which to study the effects and safety of intensive lipid
modification therapy. Individuals with heterozygous FHBL
are generally asymptomatic although case reports and some
small series have suggested that impairment of hepatic very
low-density lipoprotein (VLDL)-triglycerides (TGs)
secretion may lead to fat accumulation in the liver [38, 39].
Case–control studies have confirmed increased prevalence
and severity of hepatic steatosis, as a consequence, among
individuals with FHBL [40]. In this study, mean LDL-C
concentration among FHBL subjects was
1.04 ± 0.5 mmol/L. Abetalipoproteinaemia and homozy-
gous hypobetalipoproteinaemia are characterised by more
profound malabsorption of lipid soluble vitamins leading to
retinal degeneration, neuropathy and coagulopathy [36].
Lipid profiles with these disorders would show nearly
absent LDL (\0.1 mmol/L) and apoB (\0.1 g/L). Non-
sense mutations in PCSK9 are also associated with low
plasma levels of LDL-C and apoB, but in heterozygotes,
the levels are not as low as in abetalipoproteinaemia and
homozygous hypobetalipoproteinaemia and no systemic
involvement is seen [36].
Non-sense mutations in PCSK9 are associated with
around a 30% reduction in plasma LDL-C levels and
confer an 88% reduction in CHD events with no apparent
adverse effects [14, 41]. In addition to its role in the study
of cardioprotection with PCSK9 variants, Mendelian ran-
domisation can also be used to examine the safety mes-
sages of genetically determined low plasma LDL-C levels.
A study by Folsom et al. using data from ARIC investi-
gated whether any association existed between PCSK9
variants and cancer [42]. The rationale for this study was
based on observations from historical epidemiological
studies that identified a modest association between low
plasma cholesterol levels and cancer incidence [43, 44].
The mechanism for this association was not clear and
several reports from the 1990s suggested it was likely to be
an example of reverse causality, where cancer could result
in low plasma LDL-C and total cholesterol [43, 45]. The
ARIC analysis found that lifelong low cholesterol con-
centration, as reflected by PCSK9 variants in black and
white individuals, was not associated with increased risk of
cancer.
Residual risk on statin therapy
Meta-analyses of statin trials provide evidence of signifi-
cant on-treatment residual risk, with 5-year major CV event
rates of 22% among individuals with prior CVD and 10%
among those without prior disease [5, 46]. Pooled data
support the concept of LDL-C as a marker of residual risk,
even with LDL-C levels\2 mmol/L (\77 mg/dL) [5, 6].
Among patients with stable coronary disease in the Treat-
ing to New Targets (TNT) trial, 8.7% of patients receiving
atorvastatin 80 mg with on-treatment LDL-C concentra-
tions of 1.8–2.6 mmol/L (70–100 mg/dL) experienced a
major event over 5 years [47]. The harbingers of this
residual risk can be classified into lipid-related and non-
lipid factors. In terms of the lipid-related factors, HDL
cholesterol and TGs are commonly implicated [48]; how-
ever, the evidence to support an independent association of
either of these parameters with major CV events is
inconsistent irrespective of adjustment for apolipoproteins
[49–53]. Similarly, while on-treatment LDL-C was pre-
dictive of outcome in JUPITER [54], this finding was not
replicated in other studies after adjustment was made for
apolipoproteins and other clinical risk factors [55]. It is
noteworthy that statins can modify the plasma concentra-
tions of most atherogenic lipids and isolating the influence
of individual lipid parameters on cardiovascular risk is
complicated.
A significant proportion of selected populations in sec-
ondary prevention trials with high-dose statin do not obtain
optimal LDL-C levels, despite close monitoring of adher-
ence that is not feasible in clinical practice. As such, the
removal of specific lipid goals in the 2013 American
College of Cardiology (ACC)/American Heart Association
(AHA) guidelines [16], leaves little scope for residual risk
assessment when response to treatment is inadequate.
Accordingly, there is no support in the guidance for the use
of additional lipid-lowering therapies among those with
high absolute risk who are on maximal statin therapy or
who have achieved a 50% reduction in LDL-C. This leaves
an important modifiable risk factor, high LDL-C despite
statin therapy, not monitored neither addressed in many
patients.
Deployment of statin therapy and side effects
In 2007 the National Institute for Health and Care Excel-
lence (NICE) issued guidance recommending statin ther-
apy for primary prevention in individuals with a C20%
10-year risk of developing CVD [12]. It resulted in a sig-
nificant increase in statin therapy for high-risk individuals,
with UK population data suggesting treatment increased
242 Clin Res Cardiol (2017) 106:237–248
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from 7.0% prior to 2007 to 30.4% from 2007 onwards [56].
More recent guidance documents from NICE have advo-
cated even a lower threshold for statin treatment, at 10%
10-year risk CVD risk [57]. The perceived medicalization
of a growing number of patients being offered statin ther-
apy as a result of the lower threshold for treatment has also
placed a significant burden on primary care providers [58].
The side effects associated with statin use are well
documented in the medical literature and lay press [59].
However; adverse effects on standard doses of statin
therapy are unusual; the incidence rate of myopathy is
thought to be around one patient in 10,000 person years on
treatment [60], and the adverse effects are reversed fol-
lowing discontinuation of statins. Furthermore, the major-
ity of muscle symptoms that occurs on-treatment with
statins are not thought to be attributable to statins them-
selves [60]. Liver disease as a result of statin therapy is also
rare, meta-analysis of three randomised trials of pravastatin
showed that hepatobiliary disorders were less frequently
recorded in groups on statin as compared with placebo.
Among the strongest signal for a side-effect associated
with statin therapy is peripheral neuropathy which is
thought to occur at a rate of around 1 per 10,000 person
years on treatment [60]. What remains irreversible is the
significant morbidity and mortality associated with
atherosclerotic CVD. A recent concerning report suggests
that negative news stories concerning side effects with
statin therapy have implications for adherence on a popu-
lation level and cause significant harm in terms of pre-
ventable CVD events and death [61].
The adoption of a more targeted approach to identify
individuals who will benefit most from statin therapy by
considering pre-treatment cholesterol values as well as
absolute CVD risk has been suggested [62]. The number of
patients requiring treatment to prevent a CVD event with
statin treatment has been shown to differ markedly
according to the pre-treatment LDL-C concentration even
when absolute CVD risk is similar [63]. It produces more
likelihood of benefit when pre-treatment LDL-C concen-
tration is initially high because the reduction in LDL-C is
greater. Atorvastatin 80 mg daily (recommended by both
NICE and the ACC/AHA for high-risk patients such as
those who have already experienced a CVD event) pro-
duces a 55% decrease in LDL-C [12, 55]. Thus, in indi-
viduals with an initial LDL-C of 2.5 mmol/L, atorvastatin
80 mg daily will typically reduce LDL-C to 1.125 mmol/L,
whereas an estimated reduction to 2.5 mmol/L would be
anticipated in a patient with a pre-treatment LDL-C of
5.5 mmol/L. It may come as a surprise to many healthcare
professionals that some opinion leaders are advocating
LDL-C lowering to levels as low as or lower than
1.125 mmol/L; however, these calls are based on the evi-
dence reviewed in this article and are a rational translation
of the evidence into clinical practice. The present author’s
opinion is that it remains highly irrational to have this low
target restricted to individuals with low pre-treatment
LDL-C concentration. In such cases, there is a greater
likelihood that an incident CVD event would be
attributable to risk factors other than LDL-C. If the current
guideline algorithm from NICE is followed, a patient with
a higher pre-treatment LDL-C may remain with an LDL-C
level at 2.5 mmol/L and not receive adjunctive therapy to
achieve a similar LDL-C (1.125 mmol/L) to that of a
patient with a starting value of 2.5 mmol/L. Table 2 shows
that when the risk of a further CVD event is say 40% over
the next 10 years, more events are prevented in patients
with a higher pre-treatment LDL-C, and even more when
greater LDL-C reductions are achieved in patients with
high starting values.
Achievement of LDL-C targets
Many questions about the dissemination of cholesterol
guidelines and their impact on practice remain; the mag-
nitude of benefit in terms of LDL-C reduction and
Table 2 Prevention of cardiovascular disease events according to pre- and on-treatment LDL-C levels among individuals at high risk of CVD
Case study 1 Case study 2
10-year CVD risk 40% 40%








CVD events prevented per 100 patients treated with atorvastatin 80 mg dailya 12 21
CVD events prevented per 100 patients treated when LDL-C reduced to 1.125 mmol/L with
atorvastatin 80 mg plus adjunctive treatment (if necessary)a
12 27
CVD cardiovascular disease, LDL-C low-density lipoprotein cholesterol
a Based on risk ratio of 0.78 for cardiovascular disease event associated with each 1 mmol/L reduction in LDL-C [5]. Calculation: CVD events
prevented/100 patients treated = 40(1 - 0.78LDL-C reduction) [62, 63]
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subsequent risk reduction observed in clinical trials on
which guidelines are based has not been translated on a
population-level. Patients with established CHD have
substantial absolute risk and are therefore considered a
priority for secondary prevention. Numerous studies based
on population data report systemic under-utilisation of lipid
lowering therapies and failure to meet targets. In an uns-
elected cohort of patients with CHD in German primary
care, just 24% achieved contemporary goals of LDL-C
\2.59 mmol/L (100 mg/dL) [64]. Registry data of patients
with established CVD and/or diabetes enrolled to the
Vascular Protection (VP) and Guidelines Orientated
Approach to Lipid Lowering (GOALL) study suggest goal
attainment in around half of patients, although this fig-
ure was reduced to 21% among patients at the highest
overall risk [65].
Qualitative review of goal attainment in at-risk patients
supports the notion that individuals at the highest absolute
risk appear to be least likely to achieve lipid goals [66]. In
the GOALL registry, poor adherence to treatment guide-
lines was not attributed to lack of physician awareness of
treatment guidelines. Instead, results suggested that poor
patient adherence, inappropriate drug or dose selection, and
limited efficacy, were all barriers to successful imple-
mentation of contemporary guidance. In the PHARMO
database from the Netherlands, over half of 59,094 indi-
viduals, each followed for the first two treatment years,
discontinued statin therapy. A 30% reduction in the risk of
hospitalisation for MI was observed among those who
persisted with statin therapy during the follow-up period
[67].
Merits of a targeted approach to LDL-C
On-treatment monitoring and targets are an important and
familiar aspect of clinical practice, and can aid communi-
cation between doctor and patient, while improving patient
compliance. Targets in well-defined treatment paradigms
are well established in hypertension, for example, and
provide primary care physicians with clear and user-
friendly tools to monitor response to treatment. The move
away from specific LDL-C targets in the 2013 ACC and
AHA guidelines was met with considerable debate
[55, 68, 69]. One reason for the marked divergence from
pre-existing guidelines [70], was the remit given to the
ACC/AHA panel, which limited the evidence considered to
RCTs and their strict inclusion criteria, i.e., the absence of
a target strategy in RCTs precludes any recommendations
for specific targets. Despite this approach, clinical deci-
sions are often required in the absence of RCT data, and the
National Lipid Association suggest that treatment goals are
a useful strategy to ensure that the intensity of therapy to
lower atherogenic cholesterol is matched to absolute risk
for a CVD event [71]. A further consequence of the
absence of specific treatment targets is the potential to
create barriers for access and reimbursement. These bar-
riers are specific to individual healthcare systems but will
likely only result in under-utilisation of effective
treatments.
The strongest argument for a return to goal strategy
exists for those with the highest overall risk and high pre-
treatment LDL-C [60]. Residual risk among patients in this
group who fail to achieve significant LDL-C reductions
could be ignored with an unmonitored approach, as the
potential for ‘fire and forget’ is ominous. In a recent
patient-level meta-analysis of statin trials, 1-year major CV
event rates were 4.4, 10.9 and 16.0% among individuals
achieving LDL-C concentrations \1.3 mmol/L, between
1.3 and 1.8 mmol/L, and between 1.8 and 2.6, respectively
[72]. This is consistent with IMPROVE-IT results. These
findings, in addition to early clinical benefit seen with more
dramatic reductions in LDL-C to levels around 1.2 mmol/L
(48 mg/dL) with PCSK9 inhibitors in OSLER and
ODYSSEY LONG TERM, will rekindle arguments for a
return to goal-directed therapy. However, based on the
previous approach taken by the ACC/AHA, this shift in
emphasis will require evidence from RCTs with a targeting
strategy.
One group of patients in whom a move away from tar-
gets may be beneficial is patients with high overall risk in
the absence of high LDL-C. These patients are likely to
have residual risk attributable to LDL-C that is potentially
modifiable by achieving lower LDL-C levels therapeuti-
cally than was previously recommended (previous target
was \1.8 mmol/L in very high risk). With the recom-
mended fixed dose statin treatment these patients will
therefore already be able to achieve and benefit from
reduction in LDL-C to levels well below 1.8 mmol/L, if
they have initially low levels of LDL-C. Atorvastatin in
doses of 20 mg daily is recommended for primary pre-
vention, which typically reduces LDL-C by 43%, and in
doses of 80 mg daily for secondary prevention, which
decreases LDL-C by on average 55% [57, 73]. Thus, in
primary prevention people with LDL-C levels
\3.16 mmol/L will generally reach values below
1.8 mmol/L and in secondary prevention patients with
initial LDL-C concentrations \4 mmol/L will achieve
lower levels than 1.8 mmol/L. Paradoxically, however,
those patients with higher initial LDL-C who are often
more at risk and could receive higher doses of atorvastatin
in primary prevention or adjunctive therapy in secondary
prevention to allow them to reach lower LDL-C targets
below 1.8 mmol/L will be left with suboptimal reductions
in LDL-C, in many cases well above the earlier target of
1.8 mmol/L.
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Individuals with FH represent a particularly high-risk
group in whom premature CHD manifests as a result of
lifelong elevated LDL-C. ESC/EAS guidelines suggest an
LDL-C target of \2.5 mmol/L in adults with FH [70].
Despite use of high-intensity statins, many adults with FH
will not achieve this. Other therapies used in combination
with statins (or as monotherapy for individuals unable to
tolerate statins) include ezetimibe, Colesevelam and
PCSK9 inhibitors. The European Medicines Agency has
approved the use of the PCSK9 inhibitors, evolocumab and
alirocumab, in adults with heterozygous familial or the
non-familial form of primary hypercholesterolaemia or
with mixed dyslipidaemia [74, 75]. Evolocumab is also
authorised in Europe for use in homozygous familial
hypercholesterolaemia. In the UK, the NICE appraisal of
this new class of lipid modification therapy is ongoing [76].
Randomised trials of PCSK9 inhibitors evolocumab and
alirocumab in FH individuals on existing lipid lowering
therapy reported LDL-C reductions of 70 and 67%,
respectively [77, 78]. The results of two large cardiovas-
cular outcomes trials randomising patients on statin therapy
to receive PCSK9 inhibition or placebo are awaited. The
FOURIER trial with evolocumab has enrolled 27,500
patients with a history of MI, ischaemic stroke or symp-
tomatic peripheral artery disease and LDL-C C1.8 mmol/L
(70 mg/dL) or non-HDL-C C2.6 mmol/L (100 mg/dL)
[79]. The ODYSSEY Outcomes trial with alirocumab dif-
fers in its inclusion criteria, and is expected to randomise
around 18,000 participants within 12 months of a hospi-
talisation for acute MI or unstable angina [80]. Patients
must fulfil either the same LDL-C or non-HDL-C criteria
as in FOURIER, or have an apolipoprotein B C2.1 mmol/L
(80 mg/dL).
Conclusions
Recent trial data evaluating combination therapy among
individuals at high risk of CVD suggests that incremental
LDL-C lowering, beyond that achieved by statin therapy
can translate into reductions in CVD event rates. The
evidence from these studies, and that from meta-analyses
of statin trials, suggests that the risk to benefit ratio remains
positive without a minimum threshold. As long-term data
to directly assess the benefit of novel treatments in CVD
prevention emerge, it is critical that the deployment of
established statin therapy is optimised to achieve its
potential. For optimum clinical effectiveness, initial LDL-
C concentration must be considered in deciding whether a
target will allow a greater decrease in LDL-C and a lower
NNT than a fixed dose regimen. Treatment targets will
produce greater benefit for patients with high pre-treatment
LDL values, but will often mean that people with lower
initial levels, if treated to a target LDL-C with the low
doses of statin required for this, will not receive the benefit
that they might from higher fixed dose statin treatment.
Individual variation in the LDL-C response to statins also
makes post-treatment cholesterol measurement essential
[81]. The same principle should be followed when new
agents like PCSK9 monoclonal antibodies are considered.
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